AUD indicates alcohol use disorder.
Heavy drinking days were defined as 5 or more drinks within a day for men and 4 or more drinks within a day for women. Baseline was defined as the 8 weeks prior to intake. End point was defined as the last 8 weeks of the treatment period. The horizontal line in the middle of each box indicates the median, while the top and bottom borders of the box mark the 75th and 25th percentiles, respectively. The diamonds indicate mean values. The whiskers above and below the boxes mark the minimum value and the maximum value, respectively. Varenicline was given as varenicline tartrate.
Positive response on the integrated response measure was defined as either No Heavy Drinking Days (NHDD), Prolonged Smoking Abstinence (PA), or both during the last 28 days of treatment. Percentages within the arrows correspond to the percentage who had a good response on the integrated measure. Missing data were treated as nonresponse. Varenicline treatment had a higher integrated response rate than placebo for men (Cohen h = 0.60) but not for women (Cohen h = –0.06). Varenicline was given as varenicline tartrate.
Customize your JAMA Network experience by selecting one or more topics from the list below.
OMalley SS, Zweben A, Fucito LM, et al. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):129–138. doi:10.1001/jamapsychiatry.2017.3544
Can treatment using varenicline tartrate and medical management reduce heavy drinking and increase smoking abstinence in individuals with alcohol use disorder and comorbid cigarette smoking?
In this phase 2, randomized, double-blind, parallel group, placebo-controlled trial involving 131 participants with alcohol use disorder, varenicline effects varied in men and women. Men taking varenicline demonstrated a benefit on measures of heavy drinking, whereas women had a better response taking placebo; 13% of participants quit smoking while taking varenicline, but no one quit while taking placebo.
Varenicline, an approved smoking-cessation medication, may have a role in the treatment of alcohol use disorder among men who smoke cigarettes.
Individuals with alcohol use disorder have high rates of cigarette smoking. Varenicline tartrate, an approved treatment for smoking cessation, may reduce both drinking and smoking.
To test the efficacy of varenicline with medical management for patients with alcohol use disorder and comorbid smoking seeking alcohol treatment, and to evaluate the secondary effects on smoking abstinence.
Design, Setting, and Participants
This phase 2, randomized, double-blind, parallel group, placebo-controlled trial was conducted at 2 outpatient clinics from September 19, 2012, to August 31, 2015. Eligible participants met alcohol-dependence criteria and reported heavy drinking (≥5 drinks for men and ≥4 drinks for women) 2 or more times per week and smoking 2 or more times per week; 131 participants were randomized to either varenicline or placebo stratified by sex and site. All analyses were of the intention-to-treat type. Data analysis was conducted from February 5, 2016, to September 29, 2017.
Varenicline tartrate, 1 mg twice daily, and matching placebo pills for 16 weeks. Medical management emphasized medication adherence for 4 weeks followed by support for changing drinking.
Main Outcomes and Measures
Percentage of heavy drinking days (PHDD) weeks 9 to 16, no heavy drinking days (NHDD) weeks 9 to 16, and prolonged smoking abstinence weeks 13 to 16.
Of 131 participants, 39 (29.8%) were women and 92 (70.2%) were men, the mean (SD) age was 42.7 (11.7) years, and the race/ethnicity self-identified by most respondents was black (69 [52.7%]). Sixty-four participants were randomized to receive varenicline, and 67 to receive placebo. Mean change in PHDD between varenicline and placebo across sex and site was not significantly different. However, a significant treatment by sex by time interaction for PHDD (F1,106 = 4.66; P = .03) revealed that varenicline compared with placebo resulted in a larger decrease in log-transformed PHDD in men (least square [LS] mean difference in change from baseline, 0.54; 95% CI, −0.09 to 1.18; P = .09; Cohen d = 0.45) but a smaller decrease in women (LS mean difference, −0.69; 95% CI, −1.63 to 0.25; P = .15; Cohen d = −0.53). Thirteen of 45 men (29%) had NHDD taking varenicline compared with 3 of 47 men (6%) taking placebo (Cohen h = 0.64; 95% CI, 0.22-1.03), whereas 1 of 19 women (5%) had NHDD compared with 5 of 20 women (25%) taking placebo (Cohen h = −0.60; 95% CI, −1.21 to 0.04). Taking varenicline, 8 of 64 participants (13%) achieved prolonged smoking abstinence; no one (0 of 67) quit smoking taking placebo (P = .003; Cohen h = 0.72; 95% CI, 0.38-1.07).
Conclusions and Relevance
Varenicline with medical management resulted in decreased heavy drinking among men and increased smoking abstinence in the overall sample. Varenicline could be considered to promote improvements in men with these dual behavioral health risks.
clinicaltrials.gov Identifier: NCT01553136
Effective interventions for reducing co-occurring health risks, such as heavy alcohol use and smoking, have the potential to benefit patients and reduce health care costs.1,2Quiz Ref ID Cigarette smoking, the leading cause of disability and death, is more than twice as common among individuals with alcohol use disorder (AUD) than among the general population,3,4 and combined smoking and heavy drinking has negative synergistic effects on health.5,6 Cigarette smoking also predicts poorer treatment outcome among patients seeking alcohol treatment.7-10 Neither naltrexone hydrochloride nor acamprosate calcium, which are approved pharmacotherapies for AUD, promotes reductions in smoking during treatment of AUD.11,12 Thus, identifying pharmacotherapies to treat both AUD and smoking represents an important step in integrating addiction treatment into mainstream health care.13
One potential medication is varenicline tartrate, which has been approved by the US Food and Drug Administration (FDA) as treatment for smoking cessation that acts at nicotinic acetylcholine receptors14-16 involved in both alcohol and nicotine reward.17 Varenicline reduced alcohol seeking and consumption18-21 and attenuated dopamine release to combined ethanol and nicotine administration22 in preclinical studies; it also reduced alcohol use in human laboratory23 and pilot smoking-cessation trials.24,25 However, two 12-week multisite studies of varenicline for the treatment of AUD in mixed samples of smokers and nonsmokers had conflicting results.26,27 Litten and colleagues26 found that varenicline resulted in a significantly lower percentage of heavy drinking days in combination with a 6-session computerized bibliotherapy. Furthermore, among the subsample of smokers, those who reduced the number of cigarettes smoked had larger reductions in drinking. Subsequently, de Bejczy and colleagues27 did not find an effect of varenicline when tested in the absence of specific psychosocial counseling. The de Bejczy et al study27 did not report smoking outcomes. The Litten et al trial26 results, however, suggested that varenicline should be tested further in patients with AUD who also smoke.
Quiz Ref IDTo further evaluate the efficacy of varenicline for AUD, we recruited individuals with comorbid AUD and smoking for a randomized, double-blind, parallel group, placebo-controlled trial at 2 sites. In addition to hypothesizing an effect on alcohol consumption, we anticipated that varenicline would promote smoking abstinence, thereby providing an added benefit. The study design adopted methods from the smoking-cessation field in which patients prepare for a future “quit date” and initiate medication prior to that date.28 Thus, our study incorporated a 4-week period on medication that emphasized medication adherence prior to active efforts to change drinking. This period was followed by 12 additional weeks of treatment to allow changes in drinking and smoking to emerge. In a study of varenicline for smoking cessation, 1-week point prevalence abstinence from smoking continued to increase over 4 weeks after the quit date,29 and in the Litten et al trial, the effects of varenicline on heavy drinking became more pronounced over time.26 Thus, the primary drinking outcome in our study—percentage of heavy drinking days (PHDD)30—was evaluated following an initial 8-week grace period. Our secondary outcome—prolonged smoking abstinence with biochemical confirmation—was assessed during the last 4 weeks of treatment, which is consistent with the efficacy and safety studies of varenicline for smoking cessation.29,31,32
This phase 2, randomized, double-blind, parallel group, placebo-controlled clinical trial evaluated the effects of varenicline combined with medical management (MM) on alcohol drinking. It involved 131 alcohol-dependent smokers seeking treatment for alcohol use but not for smoking. Its secondary aim was to evaluate the effects of varenicline on smoking cessation. Participants were seen over a 16-week treatment period and had follow-up at weeks 26, 39, and 52. The results of the recruitment and treatment period, from September 19, 2012, to August 31, 2015, are presented here. This trial was approved by the institutional review boards of Columbia University and Yale School of Medicine as well as the Western Institutional Review Board, obtained a Certificate of Confidentiality from the National Institute on Alcohol Abuse and Alcoholism, and was monitored by a Data and Safety Monitoring Board. All participants provided written informed consent. Data analysis was conducted from February 5, 2016, to September 29, 2017. See the Supplement for the trial protocol.
The trial was conducted at 2 outpatient substance abuse treatment and research facilities (one affiliated with Columbia University, New York, New York, and the other affiliated with Yale School of Medicine, New Haven, Connecticut).
Participants were recruited primarily through print, radio, and social media advertisements and community outreach to health care professionals. After initial screening, participants were invited to an in-person intake appointment. Figure 1 presents the flow of participants.
Eligible participants were men and women aged 18 to 70 years who met alcohol-dependence criteria, according to the DSM-IV-TR,33 and who reported heavy drinking 2 or more times a week for the previous 90 days and 7 or fewer consecutive days of abstinence prior to intake. After the first 24 participants, the minimum smoking criteria were expanded to increase recruitment from daily smoking (5 or more cigarettes, carbon monoxide level of 6 ppm or greater, or plasma cotinine level of 40 ng/mL or greater [to convert to nanomoles per milliliter, multiply by 5.675]) to nondaily smoking (2 or more times per week, urine cotinine level of 30 ng/mL or greater, or plasma cotinine level of 6 ng/mL or greater).
The key exclusion criteria were current, clinically significant disease or abnormality; diagnosis of a serious psychiatric illness; current suicidal ideation or lifetime history of suicidal behavior34; risk of aggression35; current diagnosis of drug dependence, excluding nicotine or marijuana; risk of clinically significant alcohol withdrawal; medications in the past 3 months to treat alcohol or tobacco dependence; and psychotropic medications in the past month (but a stable dose of selective serotonin reuptake inhibitor was allowed). Women of childbearing age could not be pregnant or nursing and had to be practicing effective contraception.
Randomization to 2 mg of varenicline tartrate (n = 64) or matching placebo pills (n = 67) was stratified by site and sex within site (block size of 4). Stratification by sex was based on findings that men and women differ in their smoking36 and drinking behavior,37,38 and their response to smoking39-41 and alcohol treatment.42-44 The randomization list was generated by our study statistician (R.G.) and was implemented through a web-based system (Endpoint Systems). Pfizer, Inc supplied active medications and matching placebo pills, and Catalent, Inc packaged the medications in blister packs dispensed at every treatment session. Participants, treatment providers, and research staff were blind to the assignment throughout the study. In 2 cases involving suicidal behavior or hospitalization for suicidality, our principal investigators (S.O. and A.Z.), who did not interact with the participant, were unblinded to meet reporting requirements.
Medication titration followed these standard doses: 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for the remainder of the 16-week treatment. After week 16, use of medication was tapered over 2 weeks (0.5 mg twice daily and then 0.5 mg daily). Dose reductions were permitted, and those who discontinued medication could continue research and counseling appointments. Quiz Ref IDDaily medication adherence was monitored through a combination of pill counts returned from blister packs and self-reported compliance with the Timeline Follow-Back procedures.45
Following randomization, participants attended 12 treatment research sessions (weeks 1, 2, 3, 4, 5, 6, 7, 9, 11, 13, 15, and 17) and met with a medical professional for MM adapted from the COMBINE study.46,47 The first 4 sessions addressed tolerability and supported medication adherence; the remaining sessions addressed finalizing drinking goals as well as developing and implementing strategies for changing drinking. Three videos were viewed during treatment to standardize the discussions regarding drinking goals and strategies. The initial session took approximately 60 minutes, and the remaining sessions took 15 to 20 minutes. Smoking cessation was not addressed, but a faxed referral to the state Tobacco Quitline was offered at the last session.
Trained research assistants administered the Timeline Follow-Back Interview48 at intake for the previous 90 days and at each session to record daily drinking and smoking. Carbon monoxide and plasma cotinine were measured at intake and at monthly sessions to confirm smoking. Adverse events using the Systematic Assessment for Treatment Emergent Effects (with individual adverse events coded as mild, moderate, severe, life threatening, or fatal),49 the Columbia Suicide Severity Rating Scale (comprising multiple subscales and score ranges),34 the Overt Aggression Scale (comprising multiple subscales and score ranges),35 and the Positive and Negative Affect Schedule (score range: 10-50, with the higher score indicating greater positive or negative affect on the corresponding subscales)50 were measured at every session. Other secondary measures were obtained but are not reported here.
All analyses were of the intention-to-treat type. The primary drinking outcome, PHDD, was summarized during the last 8 weeks of treatment and analyzed using a linear mixed model, with treatment group (varenicline or placebo), site (New York or New Haven), sex (male or female), time (baseline or end point), and all of their interactions as categorical predictors. Baseline PHDD measure was calculated over the 8 weeks prior to intake. All available data were included in the model, and an unstructured variance-covariance matrix was used. Heavy drinking day was defined as consuming 5 (for men) and 4 (for women) or more standard drinks containing 14 g of ethanol.
In accordance with FDA recommendations, we performed an analysis of responders as an efficacy end point,51,52 using the responder definition of no heavy drinking days (NHDD; never drinking 4 or more drinks within a day for women or 5 or more drinks within a day for men), during the last 8 weeks and then computed effect-size estimates by sex. The NHDD outcome was a clinical benefit53 and considered a surrogate for how patients feel and function. The FDA suggests this outcome can be assessed after a grace period if the maximal drug effect is thought to take time.
The secondary outcome, prolonged abstinence (PA) from smoking, was analyzed with Fisher exact test. Prolonged abstinence was defined as self-reported abstinence in the last 28 days, as confirmed by plasma cotinine levels of less than 6 ng/mL (changed from a cotinine level of less than 15 ng/mL to detect nondaily smoking) with missing data treated as smoking. During the final 28 days of treatment, PA was the primary within-treatment efficacy outcome in the pivotal trials of varenicline.29,32
The trial was powered for a medium effect size (Cohen d = 0.5) for the between-group difference on the primary outcome. With 64 participants per group, power to detect such an effect was at least 80%, assuming α = .05 and a 2-sided test. We did not consider site and sex effects in the power calculations. To allow for dropouts, we planned to recruit 160 participants; however, the trial closed at 131 owing to slower-than-anticipated recruitment.
All analyses were performed using SAS, version 9.4 (SAS Institute Inc). We used overall F tests for interactive and main effects in the models, and t tests for post hoc comparisons. All tests were 2-tailed, and the significance level was P = .05.
A total of 131 alcohol-dependent smokers were recruited and treated between September 19, 2012, and August 31, 2015. Among the 131 participants, 39 (29.8%) were women and 92 (70.2%) were men, the mean (SD) age was 42.7 (11.7) years, and the race/ethnicity self-identified by most respondents was black (69 [52.7%]). All participants received at least 1 medication dose (first dose was observed). Baseline characteristics by treatment group and sex are shown in Table 1.
The varenicline (n = 64) and placebo (n = 67) treatment groups were similar in the median (interquartile range [IQR]) percentage of pills taken out of the total possible pills over the 16-weeks treatment period (85% [45%-98%] vs 81% [39%-96%]). However, women receiving varenicline took fewer pills (median [IQR], 58% [20%-93%]) than did men receiving varenicline (median [IQR], 91% [55%-99%]) and were more likely than men to reduce or discontinue use of varenicline (7 of 19 [37%] vs 2 of 45 [4%]). In the placebo groups, the median (IQR) percentage of pills taken was similar for men (80% [28%-94%]) and women (83% [52%-98%]). The median (IQR) number of treatment sessions attended was comparable between men and women taking varenicline (12 [9-12] vs 12 [10-12]) and taking placebo [12 [7-12] vs 11 [11-12]). Complete drinking data were available for 38 of 45 men (84%) and for 17 of 19 women (89%) taking varenicline as well as for 36 of 47 men (77%) and 16 of 20 women (80%) taking placebo.
Quiz Ref IDOn PHDD during the last 8 weeks of treatment (log transformed), the mean change from baseline did not differ (F1,106 = 0.06; P = .80) between varenicline (least square [LS] mean [SE], 1.69 [0.20]) and placebo (LS mean [SE], 1.77 [0.20]) across sex and site. However, the results revealed a significant medication by sex by time interaction (F1,106 = 4.66; P = .03). Varenicline compared with placebo resulted in a greater decrease in PHDD in men (LS mean difference for change from baseline, 0.54; 95% CI, −0.09 to 1.18; P = .09; Cohen d = 0.45) and with a smaller decrease in PHDD in women (LS mean difference, −0.69; 95% CI, −1.63 to 0.25; P = .15; Cohen d = −0.53), as shown in Figure 2. No other treatment interactions were significant.
In a responder analysis, we examined the effect of varenicline on NHDD during the last 8 weeks of treatment.52,54 When missing data were treated as heavy drinking, 13 of 45 men (29%) had NHDD taking varenicline compared with 3 of 47 men (6%) taking placebo (Cohen h = 0.64; 95% CI, 0.22-1.03), whereas 1 of 19 women (5%) had NHDD taking varenicline compared with 5 of 20 women (25%) taking placebo (Cohen h = −0.60; 95% CI, −1.21 to 0.04). Results were similar when missing data were treated as missing.
On PA, varenicline, compared with placebo, resulted in greater abstinence from smoking during the last 28 days of treatment (8 of 64 [13%] vs 0 of 67 [0%]; P = .003; Cohen h = 0.72; 95% CI, 0.38-1.07).
Using definitions of good response for alcohol (NHDD) and smoking (PA) during the last 4 weeks of treatment, Figure 3 displays the proportion of participants, categorized by sex and treatment condition, who responded by meeting one or both outcomes or who failed to respond. On this exploratory integrated outcome, a marked advantage of varenicline over placebo was seen in men (20 of 45 [44%] vs 8 of 47 [17%]; Cohen h = 0.60) but not in women (6 of 19 [32%] vs 7 of 20 [35%]; Cohen h = −0.06).
Varenicline was generally well tolerated. On the Systematic Assessment for Treatment Emergent Effects interview (Table 2), Quiz Ref IDabnormal dreaming was reported by substantially more patients in the varenicline condition. Women taking varenicline were more likely to report this complaint (13 of 19 [68%]) than men taking varenicline (15 of 45 [33%]) and than women and men taking placebo (4 of 20 [20%] vs 11 of 47 [23%]). Three serious adverse events occurred in the active treatment group: psychiatric hospitalization for suicidal ideation, alcohol rehabilitation following suicidal behavior (trying to drink to death), and overnight hospitalization for blood pressure monitoring. Two events occurred in the placebo group: psychiatric hospitalization in the 30 days following treatment and hospitalization for an infection. On the Positive and Negative Affect Schedule scale, the mean (SD) peak change in negative affect from baseline was lower on varenicline (1.80 [5.33]) than with placebo (3.53 [5.32]). The Overt Aggression Scale and Columbia Suicide Severity Rating Scale scores were similar.
This study examined the efficacy of varenicline combined with MM for the treatment of AUD in individuals with comorbid smoking. The mean change in PHDD in the overall sample was not different by medication condition. However, varenicline had different effects on drinking in men and women. Men appeared to derive benefit from varenicline, compared with placebo, on measures of heavy drinking, whereas women did better taking placebo. Although participants were not seeking or provided smoking-cessation counseling, the overall sample receiving varenicline experienced a significant increase in 1-month prolonged smoking abstinence at the end of treatment.
Compared with previous trials26,27 that included smokers and nonsmokers with AUD, our trial enrolled smokers exclusively, had a longer treatment duration, and used a more intensive behavioral intervention that incorporated methods on preparing to quit from the literature. Unlike the Litten et al trial,26,55 which found an overall advantage of varenicline over placebo that was not moderated by sex, our study found that, on PHDD, only men appeared to benefit from varenicline combined with MM. This benefit also extended to NHDD, the FDA-preferred outcome.52 The moderating role of sex was not examined in the negative trial by de Bejczy and colleagues,27 which did not provide counseling.
In our study, sex differences in the effects of varenicline combined with MM may be due to several factors. Women differed from men on baseline characteristics (eg, greater severity of alcohol dependence; lower nicotine dependence and smoking intensity); thus, causality cannot be attributed to sex. From a methodological perspective, we permitted dose reductions to minimize adherence problems because lower varenicline doses are effective for smoking cessation.56 More women than men reduced or discontinued their dose perhaps owing to lower tolerability, a finding consistent with results in other trials indicating that women are more likely to report adverse effects from varenicline.57,58 Finally, the small sample size for women limits the reliability of effect estimates.
Varenicline resulted in significantly higher rates of smoking abstinence compared with placebo (13% vs 0%), even though participants were not seeking or provided smoking-cessation counseling. These findings have important clinical implications given that less than 10% of smokers report readiness to quit smoking in the next month59; individuals treated for alcoholism are more likely to die of smoking than from alcohol-related causes60; and smoking cessation substantially lowers the risk of lung and other cancers, coronary artery disease, stroke, peripheral vascular disease, and chronic obstructive pulmonary disease.61 Furthermore, most alcohol-dependent smokers do not receive smoking-cessation assistance, yet heavy-drinking smokers see these behaviors as highly associated.62
In an exploratory integrated responder analysis, there was little overlap in the response to varenicline on the categorical outcomes of PA and NHDD during the last 28 days of treatment. Examining good response measured by NHDD and/or PA, we observed that the marked advantage of varenicline over placebo in men vs women (44% vs 17%) was driven largely by reduced drinking. In women, the percentage who had a good response was equivalent for varenicline (32%) and placebo (35%), with smoking abstinence predominating with varenicline. For both sexes, the percentage who met the criteria for both NHDD and PA on varenicline was small, and good response in the placebo condition was related exclusively to improvements in drinking. For these analyses, we used biochemical confirmation of self-reported smoking abstinence; however, biomarkers of alcohol consumption, such as ethyl glucuronide, have not been validated for distinguishing heavy drinking from lower levels of drinking. Thus, heavy drinking may have been underreported.
Information on varenicline safety in smokers with current AUD has been limited because this population has been excluded from smoking-cessation trials.31,63 Our trial, together with 2 previous multisite trials,26,27 addresses this gap by noting low rates of adverse events, with only abnormal dreams—a common adverse event of varenicline—being substantially higher with varenicline than placebo, particularly among women. However, compared with participants in studies of smokers without current AUD,31,32 our participants reported abnormal dreams more frequently in both conditions, suggesting that patients with AUD may be at increased risk for this complaint. Of note, sleep problems are common among patients with AUD.64 Finally, negative affect scores were lower on varenicline, which is consistent with the findings of a laboratory study of smoking abstinence.65
The small sample size of women is an important limitation. Future studies should evaluate the effectiveness and safety of varenicline in women and men separately in larger samples to establish whether the observed effects are of clinical significance. Limits to the generalizability of the findings include the exclusion of those with other drug dependence, current suicidality or a history of suicidal behavior, significant irritability or aggression, and risk of significant alcohol withdrawal.
Among individuals seeking AUD treatment who also smoked cigarettes, the effect of varenicline did not differ from placebo in the overall sample, but differed between men and women. Varenicline, compared with placebo, resulted in greater reduction in heavy drinking in men but not in women. Smoking-cessation counseling was not provided, but varenicline resulted in higher smoking abstinence, which is consistent with the primary indication for varenicline. Thus, varenicline combined with MM appears to have potential as a treatment for the co-occurring health risk behaviors of heavy alcohol use and smoking in men.
Corresponding Author: Stephanie S. O’Malley, PhD, Department of Psychiatry, Yale School of Medicine, 34 Park St, New Haven, CT 06519 (firstname.lastname@example.org).
Accepted for Publication: October 2, 2017.
Published Online: December 20, 2017. doi:10.1001/jamapsychiatry.2017.3544
Author Contributions: Drs O’Malley and Zweben had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: O’Malley, Zweben, Fucito, Jatlow, Gueorguieva.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: O’Malley, Zweben, Fucito, Piepmeier, Wu, Bold, Petrakis, Muvvala, Gueorguieva.
Critical revision of the manuscript for important intellectual content: Zweben, Fucito, Ockert, Bold, Muvvala, Jatlow, Gueorguieva.
Statistical analysis: Wu, Bold, Gueorguieva.
Obtained funding: O’Malley, Zweben.
Administrative, technical, or material support: O’Malley, Zweben, Fucito, Piepmeier, Bold, Petrakis, Jatlow.
Study supervision: O’Malley, Zweben, Fucito, Ockert, Muvvala.
Conflict of Interest Disclosures: Dr O’Malley reported having been a consultant or an advisory board member for Alkermes, Amygdala, Arkeo, Cerecor, Mitsubishi Tanabe, Opiant, Pfizer; a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative supported by Abbott, Amygdala, Ethypharm, Lilly, Lundbeck, Otsuka, Pfizer, Arbor Pharmaceuticals, and Indivior; a coinvestigator on studies receiving donated medications from Astra Zeneca, Novartis; a site principal investigator for a multisite trial by Lilly; and a scientific panel member for Hazelden Foundation. Dr Petrakis reported being a consultant to Alkermes. Dr Fucito reported registering with the US Patent and Trademark Office the name and content of a web-based program to help with sleeping and drinking (ie, Call it a Night). No other disclosures were reported.
Funding/Support: This trial was supported in part by grants R01AA020388, R01AA020389, P50AA012870, T32DA019426, K23AA020000, and K05AA014715 from the National Institutes of Health and by the State of Connecticut Department of Mental Health and Addiction Services. Pfizer generously donated varenicline and placebo pills.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: This content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health, the Connecticut Department of Mental Health and Addiction Services, or the State of Connecticut.
Additional Contributions: The following people provided important contributions to the conduct of this trial: Armin Baier, JD, MSW, Parallax Center; Douglas Bass, MD, Parallax Center; David Forman, MSW, Columbia University; Elaine Lavelle, MS, Yale School of Medicine; Susan Neveu, Yale School of Medicine; and Denise Romano, APRN, MSN, MA, ADS-RT, Yale School of Medicine. These individuals were compensated for their contributions.
Create a personal account or sign in to: